about
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.A Review of Autologous Stem Cell Transplantation in Lymphoma.High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center.Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries.
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Treatment of relapsed and refractory Hodgkin Lymphoma.
@en
type
label
Treatment of relapsed and refractory Hodgkin Lymphoma.
@en
prefLabel
Treatment of relapsed and refractory Hodgkin Lymphoma.
@en
P2860
P1476
Treatment of relapsed and refractory Hodgkin Lymphoma.
@en
P2093
Bastian von Tresckow
Craig H Moskowitz
P2860
P304
P356
10.1053/J.SEMINHEMATOL.2016.05.010
P577
2016-05-12T00:00:00Z